1
|
Ma YF, Lin YA, Huang CL, Hsu CC, Wang S, Yeh SR, Tsai YC. Lactiplantibacillus plantarum PS128 Alleviates Exaggerated Cortical Beta Oscillations and Motor Deficits in the 6-Hydroxydopamine Rat Model of Parkinson's Disease. Probiotics Antimicrob Proteins 2023; 15:312-325. [PMID: 34449056 DOI: 10.1007/s12602-021-09828-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/29/2021] [Indexed: 10/20/2022]
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by midbrain dopaminergic neuronal loss and subsequent physical impairments. Levodopa manages symptoms best, while deep brain stimulation (DBS) is effective for advanced PD patients; however, side effects occur with the diminishing therapeutic window. Recently, Lactiplantibacillus plantarum PS128 (PS128) was found to elevate dopamine levels in rodent brains, suggesting its potential to prevent PD. Here, the therapeutic efficacy of PS128 was examined in the 6-hydroxydopamine rat PD model. Suppression of the power spectral density of beta oscillations (beta PSD) in the primary motor cortex (M1) was recorded as the indicator of disease progression. We found that 6 weeks of daily PS128 supplementation suppressed M1 beta PSD as well as did levodopa and DBS. Long-term normalization of M1 beta PSD was found in PS128-fed rats, whereas levodopa and DBS showed only temporal effects. PS128 + levodopa and PS128 + DBS exhibited better therapeutic effects than did levodopa + DBS or either alone. Significantly improved motor functions in PS128-fed rats were correlated with normalization of M1 beta PSD. Brain tissue analyses further demonstrated the role of PS128 in dopaminergic neuroprotection and the enhanced availability of neurotransmitters. These findings suggest that psychobiotic PS128 might be used alongside conventional therapies to treat PD patients.
Collapse
Affiliation(s)
- Yi-Fan Ma
- Biomedical Industry Ph.D. Program, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan
- Microbiome Research Center, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan
| | - Yi-An Lin
- Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, 300, Taiwan
- EzInstrument Technology Co., Ltd., Hsinchu, 300, Taiwan
| | - Chin-Lin Huang
- Microbiome Research Center, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan
- Bened Biomedical Co., Ltd., Taipei, 104, Taiwan
| | | | - Sabrina Wang
- Institute of Anatomy and Cell Biology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
| | - Shih-Rung Yeh
- Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, 300, Taiwan.
| | - Ying-Chieh Tsai
- Biomedical Industry Ph.D. Program, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
- Microbiome Research Center, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
- Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
| |
Collapse
|
2
|
Wu SI, Wu CC, Cheng LH, Noble SW, Liu CJ, Lee YH, Lin CJ, Hsu CC, Chen WL, Tsai PJ, Kuo PH, Tsai YC. Psychobiotic supplementation of HK-PS23 improves anxiety in highly stressed clinical nurses: a double-blind randomized placebo-controlled study. Food Funct 2022; 13:8907-8919. [PMID: 35924970 DOI: 10.1039/d2fo01156e] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Nurses often experience adverse health effects associated with increasing levels of work-related stress. Stress may induce systemic effects through the HPA axis, glucocorticoid responses, and inflammatory cascades. Psychobiotics may help alleviate stress through associations of the microbiota, anti-inflammation factors, and the gut-brain axis. We aimed to investigate whether interventions with a psychobiotic, heat-killed (HK)-PS23 cells, may help improve perceived stress, anxiety, and related biological markers among highly stressed clinical nurses. This double-blind, randomized, placebo-controlled study included seventy clinical nurses from a medical center in Northern Taiwan who scored 27 or higher on the 10-item version of the Perceived Stress Scale (PSS), and participants were randomized into either taking HK-PS23 or a placebo for 8 weeks. Baseline and endpoint results of the PSS, Job Stress Scale, State and Trait Anxiety Index (STAI), emotional questionnaires, gastrointestinal severity questionnaires, Trails Marking Tests, blood biological markers, and sleep data were analyzed. While both groups demonstrated improvements in most measures over time, only the blood cortisol measure demonstrated significant group differences after the 8-week trial. Further analyses of the subgroup with higher anxiety (nurses with STAI ≥ 103) revealed that anxiety states had improved significantly in the HK-PS23 group but not in the placebo group. In summary, this placebo-controlled trial found significant reduction in the level of blood cortisol after 8 weeks of HK-PS23 use. The distinctive anxiolytic effects of HK-PS23 may be beneficial in improving perceived anxiety and stress hormone levels in female nurses under pressure. Clinical trial registration: https://clinicaltrials.gov/, identifier: NCT04452253-sub-project 1.
Collapse
Affiliation(s)
- Shu-I Wu
- Department of Medicine, MacKay Medical College, New Taipei City, Taiwan. .,Section of Psychiatry and Suicide Prevention Center, MacKay Memorial Hospital, Taipei, Taiwan
| | | | | | | | - Chih-Ju Liu
- Department of Nursing, Mackay Memorial Hospital, Taipei, Taiwan
| | - Yu-Hsia Lee
- Department of Nursing, Mackay Memorial Hospital, Taipei, Taiwan
| | - Chen-Ju Lin
- Section of Psychiatry and Suicide Prevention Center, MacKay Memorial Hospital, Taipei, Taiwan
| | | | - Wan-Lin Chen
- Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
| | | | - Po-Hsiu Kuo
- Department of Public Health & Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.,Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan
| | - Ying-Chieh Tsai
- Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei, Taiwan
| |
Collapse
|
3
|
Huang HJ, Chen JL, Liao JF, Chen YH, Chieu MW, Ke YY, Hsu CC, Tsai YC, Hsieh-Li HM. Lactobacillus plantarum PS128 prevents cognitive dysfunction in Alzheimer's disease mice by modulating propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis. BMC Complement Med Ther 2021; 21:259. [PMID: 34627204 PMCID: PMC8502419 DOI: 10.1186/s12906-021-03426-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Accepted: 09/27/2021] [Indexed: 12/27/2022] Open
Abstract
Background According to recent evidence, psychobiotics exert beneficial effects on central nervous system-related diseases, such as mental disorders. Lactobacillus plantarum PS128 (PS128), a novel psychobiotic strain, improves motor function, depression, and anxiety behaviors. However, the psychobiotic effects and mechanisms of PS128 in Alzheimer’s disease (AD) remain to be explored. Objectives The goal of the current study was to evaluate the beneficial effects of PS128 and to further elucidate its mechanism in AD mice. Methods PS128 (1010 colony-forming unit (CFU)/ml) was administered via oral gavage (o.g.) to 6-month-old male wild-type B6 and 3 × Tg-AD mice (harboring the PS1M146V, APPswe and TauP30IL transgenes) that received an intracerebroventricular injection of streptozotocin (icv-STZ, 3 mg/kg) or vehicle (saline) for 33 days. After serial behavioral tests, fecal short-chain fatty acid levels and AD-related pathology were assessed in these mice. Results Our findings show that intracerebroventricular injection of streptozotocin accelerated cognitive dysfunction associated with increasing levels of glycogen synthase kinase 3 beta (GSK3β) activity, tau protein phosphorylation at the T231 site (pT231), amyloid-β (Aβ) deposition, amyloid-β protein precursor (AβPP), β-site AβPP-cleaving enzyme (BACE1), gliosis, fecal propionic acid (PPA) levels and cognition-related neuronal loss and decreasing postsynaptic density protein 95 (PSD95) levels in 3 × Tg-AD mice. PS128 supplementation effectively prevented the damage induced by intracerebroventricular injection of streptozotocin in 3 × Tg-AD mice. Conclusions Based on the experimental results, intracerebroventricular injection of streptozotocin accelerates the progression of AD in the 3 × Tg-AD mice, primarily by increasing the levels of gliosis, which were mediated by the propionic acid and glycogen synthase kinase 3 beta pathways. PS128 supplementation prevents damage induced by intracerebroventricular injection of streptozotocin by regulating the propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis in 3 × Tg-AD mice. Therefore, we suggest that PS128 supplementation is a potential strategy to prevent and/or delay the progression of AD. Supplementary Information The online version contains supplementary material available at 10.1186/s12906-021-03426-8.
Collapse
Affiliation(s)
- Hei-Jen Huang
- Department of Nursing, MacKay Junior College of Medicine, Nursing and Management, Taipei, 11260, Taiwan
| | - Jie-Ling Chen
- Department of Life Science, National Taiwan Normal University, Taipei, 11677, Taiwan
| | - Jian-Fu Liao
- Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan
| | - Yu-Hsin Chen
- Department of Nursing, MacKay Junior College of Medicine, Nursing and Management, Taipei, 11260, Taiwan
| | - Min-Wei Chieu
- Department of Nursing, MacKay Junior College of Medicine, Nursing and Management, Taipei, 11260, Taiwan
| | - Ya-Yun Ke
- Department of Life Science, National Taiwan Normal University, Taipei, 11677, Taiwan
| | | | - Ying-Chieh Tsai
- Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan.
| | - Hsiu Mei Hsieh-Li
- Department of Life Science, National Taiwan Normal University, Taipei, 11677, Taiwan.
| |
Collapse
|
4
|
Park S, Lim J, Lee KT, Oh MS, Jang DS. Single and Repeated Oral Dose Toxicity and Genotoxicity of the Leaves of Butterbur. Foods 2021; 10:foods10081963. [PMID: 34441739 PMCID: PMC8394925 DOI: 10.3390/foods10081963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 08/19/2021] [Accepted: 08/19/2021] [Indexed: 11/23/2022] Open
Abstract
Butterbur (Petasites japonicus (Siebold & Zucc.) Maxim) leaves are available to consumers in the marketplace, but there is no guarantee that they are safe for human consumption. Previously, we demonstrated that hot water extracts of P. japonicus leaves (KP-1) had anti-inflammatory properties and attenuated memory impairment. However, data regarding KP-1 toxicity are lacking. This study assessed the safety of KP-1 by examining oral and genotoxic effects using in vivo and in vitro tests, respectively. In a single oral dose toxicity and two-week repeated oral dose toxicity study, we observed no toxicologically significant clinical signs or changes in hematology, blood chemistry, and organ weights at any dose during the experiment. Following a thirteen-week repeated oral dose, toxicity, hyperkeratosis, and squamous cell hyperplasia of the limiting ridge in the stomach were observed. The no observable adverse effect level (NOAEL) was found to be 1250 mg/kg/day in male and female rats. However, hyperkeratosis and hyperplasia were not considered to be of toxicological significance when extrapolating the NOAEL to humans because the limiting ridge in the stomach is species-specific to rats. Therefore, in our study, the NOAEL was considered to be 5000 mg/kg/day when the changes in the stomach’s limiting ridge were discounted. Moreover, in vitro bacterial reverse mutations and chromosomal aberrations in Chinese hamster lung (CHL) cells and the in vivo micronucleus in Institute of cancer research (ICR) mice assays showed that KP-1 possessed no mutagenicity. Although additional research is required, these toxicological evaluations suggest that KP-1 could be safe for human consumption.
Collapse
Affiliation(s)
- Sangsu Park
- Department of Fundamental Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Korea;
| | - Jeongin Lim
- NATUREBIO Co., Ltd., Seoul Biohub Industry-Academic Cooperation Center, Seoul 02447, Korea;
| | - Kyung Tae Lee
- Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea;
| | - Myung Sook Oh
- Department of Oriental Pharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea;
| | - Dae Sik Jang
- Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Korea
- Correspondence: ; Tel.: +82-2-961-0719
| |
Collapse
|
5
|
Lu H, Zhao W, Liu WH, Sun T, Lou H, Wei T, Hung WL, Chen Q. Safety Evaluation of Bifidobacterium lactis BL-99 and Lacticaseibacillus paracasei K56 and ET-22 in vitro and in vivo. Front Microbiol 2021; 12:686541. [PMID: 34394030 PMCID: PMC8358461 DOI: 10.3389/fmicb.2021.686541] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Accepted: 06/25/2021] [Indexed: 12/12/2022] Open
Abstract
Probiotics have been reported to play a major role in maintaining the balance of microbiota in host. Consumption of food with probiotics has increased with consumer concerns regarding healthy diets and wellness. Correspondingly, safety evaluation of probiotics for human consumption has become increasingly important in food industry. Herein, we aimed to test the safety of Bifidobacterium lactis BL-99 and Lacticaseibacillus paracasei K56 and ET-22 strains in vitro and in vivo. In results, these strains were found to be negative for mucin degradation and platelet aggregation test. Additionally, the three strains were susceptible to eight antibiotics. In accordance with bacterial reversion mutation (Ames) assay, the tested strains had no genetic mutagenicity. Finally, it was confirmed that there were no dose-dependent mortality and toxicity throughout multidose oral toxicity tests in rats. Our findings demonstrated that B. lactis BL-99 and L. paracasei K56 and ET-22 can achieve the generally recognized as safe (GRAS) status as probiotics in the future.
Collapse
Affiliation(s)
- Hongyun Lu
- Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China
| | - Wen Zhao
- Inner Mongolia Dairy Technology Research Institute Co., Ltd., Hohhot, China
- Yili Innovation Center, Inner Mongolia Yili Industrial Group Co., Ltd., Hohhot, China
| | - Wei-Hsien Liu
- Inner Mongolia Dairy Technology Research Institute Co., Ltd., Hohhot, China
- Yili Innovation Center, Inner Mongolia Yili Industrial Group Co., Ltd., Hohhot, China
| | - Ting Sun
- Inner Mongolia Dairy Technology Research Institute Co., Ltd., Hohhot, China
- Yili Innovation Center, Inner Mongolia Yili Industrial Group Co., Ltd., Hohhot, China
| | - Hanghang Lou
- Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China
| | - Tianyu Wei
- Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China
| | - Wei-Lian Hung
- Inner Mongolia Dairy Technology Research Institute Co., Ltd., Hohhot, China
- Yili Innovation Center, Inner Mongolia Yili Industrial Group Co., Ltd., Hohhot, China
| | - Qihe Chen
- Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China
| |
Collapse
|
6
|
Lu CS, Chang HC, Weng YH, Chen CC, Kuo YS, Tsai YC. The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson's Disease: A Pilot Study. Front Nutr 2021; 8:650053. [PMID: 34277679 PMCID: PMC8277995 DOI: 10.3389/fnut.2021.650053] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Accepted: 06/04/2021] [Indexed: 12/12/2022] Open
Abstract
Background: Lactobacillus plantarum PS128 (PS128) is a specific probiotic, known as a psychobiotic, which has been demonstrated to alleviate motor deficits and inhibit neurodegenerative processes in Parkinson's disease (PD)-model mice. We hypothesize that it may also be beneficial to patients with PD based on the possible mechanism via the microbiome-gut-brain axis. Methods: This is an open-label, single-arm, baseline-controlled trial. The eligible participants were scheduled to take 60 billion colony-forming units of PS128 once per night for 12 weeks. Clinical assessments were conducted using the Unified Parkinson's Disease Rating Scale (UPDRS), modified Hoehn and Yahr scale, and change in patient "ON-OFF" diary recording as primary outcome measures. The non-motor symptoms questionnaire, Beck depression inventory-II, patient assessment of constipation symptom, 39-item Parkinson's Disease Questionnaire (PDQ-39), and Patient Global Impression of Change (PGI-C) were assessed as secondary outcome measures. Results: Twenty-five eligible patients (32% women) completed the study. The mean age was 61.84 ± 5.74 years (range, 52-72), mean disease duration was 10.12 ± 2.3 years (range, 5-14), and levodopa equivalent daily dosage was 1063.4 ± 209.5 mg/daily (range, 675-1,560). All patients remained on the same dosage of anti-parkinsonian and other drugs throughout the study. After 12 weeks of PS128 supplementation, the UPDRS motor scores improved significantly in both the OFF and ON states (p = 0.004 and p = 0.007, respectively). In addition, PS128 intervention significantly improved the duration of the ON period and OFF period as well as PDQ-39 values. However, no obvious effect of PS128 on non-motor symptoms of patients with PD was observed. Notably, the PGI-C scores improved in 17 patients (68%). PS128 intervention was also found to significantly reduce plasma myeloperoxidase and urine creatinine levels. Conclusion: The present study demonstrated that PS128 supplementation for 12 weeks with constant anti-parkinsonian medication improved the UPDRS motor score and quality of life of PD patients. We suggest that PS128 could serve as a therapeutic adjuvant for the treatment of PD. In the future, placebo-controlled studies are needed to further support the efficacy of PS128 supplementation. Clinical Trial Registration: https://clinicaltrials.gov/, identifier: NCT04389762.
Collapse
Affiliation(s)
- Chin-Song Lu
- Professor Lu Neurological Clinic, Taoyuan, Taiwan
| | | | - Yi-Hsin Weng
- Division of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.,School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.,Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
| | - Chiung-Chu Chen
- Division of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.,School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.,Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
| | - Yi-Shan Kuo
- Professor Lu Neurological Clinic, Taoyuan, Taiwan
| | - Ying-Chieh Tsai
- Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei, Taiwan
| |
Collapse
|
7
|
Kong XJ, Liu J, Liu K, Koh M, Sherman H, Liu S, Tian R, Sukijthamapan P, Wang J, Fong M, Xu L, Clairmont C, Jeong MS, Li A, Lopes M, Hagan V, Dutton T, Chan ST(P, Lee H, Kendall A, Kwong K, Song Y. Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial. Nutrients 2021; 13:1552. [PMID: 34062986 PMCID: PMC8147925 DOI: 10.3390/nu13051552] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 05/01/2021] [Accepted: 05/02/2021] [Indexed: 12/14/2022] Open
Abstract
Autism spectrum disorder (ASD) is a rapidly growing neurodevelopmental disorder. Both probiotics and oxytocin were reported to have therapeutic potential; however, the combination therapy has not yet been studied. We conducted a randomized, double-blinded, placebo-controlled, 2-stage pilot trial in 35 individuals with ASD aged 3-20 years (median = 10.30 years). Subjects were randomly assigned to receive daily Lactobacillus plantarum PS128 probiotic (6 × 1010 CFUs) or a placebo for 28 weeks; starting on week 16, both groups received oxytocin. The primary outcomes measure socio-behavioral severity using the Social Responsiveness Scale (SRS) and Aberrant Behavior Checklist (ABC). The secondary outcomes include measures of the Clinical Global Impression (CGI) scale, fecal microbiome, blood serum inflammatory markers, and oxytocin. All outcomes were compared between the two groups at baseline, 16 weeks, and 28 weeks into treatment. We observed improvements in ABC and SRS scores and significant improvements in CGI-improvement between those receiving probiotics and oxytocin combination therapy compared to those receiving placebo (p < 0.05). A significant number of favorable gut microbiome network hubs were also identified after combination therapy (p < 0.05). The favorable social cognition response of the combination regimen is highly correlated with the abundance of the Eubacterium hallii group. Our findings suggest synergic effects between probiotics PS128 and oxytocin in ASD patients, although further investigation is warranted.
Collapse
Affiliation(s)
- Xue-Jun Kong
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
- Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Jun Liu
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
- Harvard Medical School, Boston, MA 02115, USA; (P.S.); (L.X.); (H.L.)
| | - Kevin Liu
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Madelyn Koh
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Hannah Sherman
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Siyu Liu
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Ruiyi Tian
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | | | - Jiuju Wang
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Michelle Fong
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Lei Xu
- Harvard Medical School, Boston, MA 02115, USA; (P.S.); (L.X.); (H.L.)
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Cullen Clairmont
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Min-Seo Jeong
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Alice Li
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Maria Lopes
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Veronica Hagan
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Tess Dutton
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Suk-Tak (Phoebe) Chan
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Hang Lee
- Harvard Medical School, Boston, MA 02115, USA; (P.S.); (L.X.); (H.L.)
- MGH Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Amy Kendall
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Kenneth Kwong
- Athinoula A. Martinos Center, Massachusetts General Hospital, Charlestown, MA 02129, USA; (J.L.); (K.L.); (M.K.); (H.S.); (S.L.); (R.T.); (J.W.); (M.F.); (C.C.); (M.-S.J.); (A.L.); (M.L.); (V.H.); (T.D.); (S.-T.C.); (A.K.); (K.K.)
| | - Yiqing Song
- Department of Epidemiology, Indiana University, Richard M. Fairbanks School of Public Health, Indianapolis, IN 46202, USA;
| |
Collapse
|
8
|
Wu SI, Wu CC, Tsai PJ, Cheng LH, Hsu CC, Shan IK, Chan PY, Lin TW, Ko CJ, Chen WL, Tsai YC. Psychobiotic Supplementation of PS128 TM Improves Stress, Anxiety, and Insomnia in Highly Stressed Information Technology Specialists: A Pilot Study. Front Nutr 2021; 8:614105. [PMID: 33842519 PMCID: PMC8032933 DOI: 10.3389/fnut.2021.614105] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Accepted: 03/05/2021] [Indexed: 12/28/2022] Open
Abstract
Background: Information technology (IT) is an industry related to the production of computers, information processing, and telecommunications. Such industries heavily rely on the knowledge and solutions provided by IT specialists. Previous reports found that the subjective stress scores were higher in IT specialists who developed diabetes, hypertension, and depression. Specific probiotics, known as psychobiotics, may alleviate stress and mood symptoms. This study aimed to examine whether an 8-week intervention of a novel psychobiotic, Lactobacillus plantarum PS128TM (PS128TM), improved self-perceived stress and mood symptoms among high-stress IT specialists. Methods: This open-label, single-arm, baseline-controlled study included IT specialists from a large IT company in Northern Taiwan. Participants with a Perceived Stress Scale (PSS) 10-item version score of 27 or higher were included. Participants were asked to take two capsules containing PS128TM powder, equivalent to 20 billion colony-forming units, daily. Self-report measures, such as the Job Stress Scale, Visual Analog Scale of Stress, the Insomnia Severity Index, the State and Trait Anxiety Index, the Questionnaire for Emotional Trait and State, the Patient Health Questionnaire, the Quality of Life Enjoyment and Satisfaction Questionnaire, and Gastrointestinal Severity Index were compared at baseline and at the end of the trial period. The primary outcome was a 20% reduction in the PSS score at endpoint. Objective measures included salivary levels of stress biomarkers, including cortisol, α-amylase, immunoglobulin A, lactoferrin, and lysozymes, as well as results of the Test of Attentional Performance. Results: Of the 90 eligible IT specialists, 36 met the inclusion criteria. After the 8-week trial period, significant improvements in self-perceived stress, overall job stress, job burden, cortisol level, general or psychological health, anxiety, depression, sleep disturbances, quality of life, and both positive and negative emotions were found. Conclusion: Our results suggest that PS128TM has the distinct advantage of providing stress relief and can improve mental health for people with a high-stress job. Future placebo-controlled studies are warranted to explore the effect and underlying mechanisms of action of PS128TM. Clinical Trial Registration:https://clinicaltrials.gov/ (identifier: NCT04452253-sub-project 2).
Collapse
Affiliation(s)
- Shu-I Wu
- Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.,Section of Psychiatry and Suicide Prevention Center, MacKay Memorial Hospital, Taipei, Taiwan
| | | | | | | | | | - Ian-Kai Shan
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Po-Ying Chan
- Department of Medicine, MacKay Medical College, New Taipei City, Taiwan
| | - Ting-Wei Lin
- Department of Medicine, MacKay Medical College, New Taipei City, Taiwan
| | - Chih-Jung Ko
- Department of Medicine, MacKay Medical College, New Taipei City, Taiwan
| | - Wan-Lin Chen
- Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
| | - Ying-Chieh Tsai
- Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei, Taiwan
| |
Collapse
|